DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1494)

TreatmentTrends: Hospital Discharge and Outpatient Parenteral Antibiotic Therapy 2014 (US)

TreatmentTrends: Hospital Discharge and Outpatient Parenteral Antibiotic Therapy 2014 (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Outpatient parenteral antimicrobial therapy (OPAT) has become a wide-spread practice in the United States. The growth of the OPAT market has been driven by its potential to reduce healthcare costs, improve conven-ience for patients and decrease the risk of complications due to hospitalization. Patients with infections requiring often prolonged treatment with intravenous antibiotics and having a relatively low risk of developing fulmi-nant disease are the best candidates for receiving OPAT. This report provides insight into the management of hospitalized antibiotic-treated patients after discharge and in the outpatient setting, with an emphasis on OPAT treatment. Through market research with infectious diseases specialists, the report analyzes the post-hospital antibiotic prescribing practices for the treatment of key infections due to emerging and clinically-important pathogens, including MRSA, and identifies factors that drive and constrain physician prescribing of key OPAT therapies. The report will also explore the impact of the emerging long-acting glycolipopeptides on OPAT treatment and hospitalization decisions.

Questions Answered in This Report:

  • - Which patient populations are suitable for OPAT therapy after dis-charge? What are the sites of OPAT administration and reasons for treatment switching and discontinuation.

  • - How do physicians make OPAT treatment choices for patients with a variety of infections, including MRSA and Gram-negative infections. What drives OPAT initiation and what are the preferred therapies?

  • - Which drug attributes influence physicians’ current and future pre-scribing? What are the strengths and drawbacks of current OPAT therapies? Which drug attributes are valued for the outpatient setting?

  • - What is the level of ID physicians’ receptivity to emerging therapies for use in OPAT and in the outpatient setting. How do physicians per-ceive the competitive potential of long-acting glycolipopeptides — Durata’s dalbavancin and The Medicines Company’s oritavancin?


Sample Frame & Methodology:

- ~100 infectious diseases specialists complete a 45-minute online quanti-tative survey with several open-ended questions for qualitative feedback.

To qualify, respondents must meet the following criteria:

- Be board-certified in infectious diseases and affiliated with a hospital

- Have been in practice a minimum of 2 years and a maximum of 30 years

- At least 20 percent of practice in the hospital, inpatient setting

- Have prescribed OPAT to a minimum of 10 patients during the previ-ous month

Key Drugs Covered:

- Cubicin (daptomycin), Zyvox (linezolid), Tygacil (tigecycline), Invanz (ertapenem), vancomycin (generics), Merrem (meropenem), Zosyn (piperacillin/tazobactam), Teflaro (ceftaroline), Vibativ (telavancin), Doribax (doripenem), dalbavancin, oritavancin and tedizolid.

Key Companies Mentioned:

- AstraZeneca, Cubist, Durata, Forest Laboratories, Johnson & Johnson/Janssen, Merck, Pfizer and The Medicines Company


- Final report in Powerpoint format

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions

Related Reports:

- DecisionBase®: Gram-Negative Infections

- DecisionBase®: MRSA and Complicated Skin and Skin Structure Infec-tions

- Pharmacor®: Hospital-Treated Gram-Negative Infections

- Pharmacor®: Hospital-Treated Infections

- Physician and Payer Forum® (U.S.): Gram-Negative Infections

- Physician and Payer Forum® (U.S.): MRSA Infections

- Physician and Payer Forum® (China): Hospital-Treated Infections

- TreatmentTrends® (US): MRSA Infections

- TreatmentTrends® (EU): Gram-Negative Infections

  • Pub Date: June 2014

Request report

Related reports: